$1.27
▲ +3.2% Today
as of Oct 23, 15:05 ET
Last 30 days
Recent Press Releases & News
RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RNXT earnings at a glance
Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±3.2% on average; after the most recent report on May 14, 2026 it moved +0.7%. RNXT beat the consensus EPS estimate in 0 of its last 4 reported quarters. The share price of $1.27 sits in the middle of its 52-week range.
Overview
52-week range
$0.70
$2.59
30% of range
Avg surprise (last 4)
0.0%
Avg reaction (last 2)
+3.2%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.06 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-0.08 | $-0.08 | 0.0% | 0.0% | +0.7% | earnings |
| Thu Nov 13, 2025 | Sep/2025 | $-0.08 | $-0.08 | 0.0% | — | — | earnings |
| Thu Aug 14, 2025 | Jun/2025 | $-0.08 | $-0.08 | 0.0% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.08 | $-0.08 | 0.0% | — | +5.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.10 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.10 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.13 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.22 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.36 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $909,000 | $563,000 | — | $266,000 | $422,000 | $197,000 | — | — |
| Cost of revenue | $143,000 | $84,000 | — | $53,000 | $152,000 | $94,000 | — | — |
| Gross profit | $766,000 | $479,000 | — | $213,000 | $270,000 | $103,000 | — | — |
| Operating income | $-3M | $-3M | — | $-3M | $-3M | $-3M | — | $-3M |
| Net income | $-3M | $-4M | — | $-3M | $-3M | $-2M | — | $-2M |
| EPS (diluted) | $-0.06 | $-0.09 | — | $-0.08 | $-0.08 | $-0.08 | — | $-0.10 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $9M | $12M | $7M | $10M | $12M | $15M | $7M | $10M |
| Inventory | $383,000 | $379,000 | $189,000 | $272,000 | — | — | — | — |
| Total current assets | $11M | $14M | $8M | $11M | $13M | $16M | $8M | — |
| Total assets | $11M | $14M | $8M | $11M | $14M | $16M | $8M | $10M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $2M | $3M | $3M | $3M | $3M | $3M | $4M | $3M |
| Total equity | $9M | $11M | $5M | $8M | $11M | $13M | $4M | $7M |
Implied volatility — last 90 days
No IV snapshots yet for RNXT.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.
Sector peers
RNXT earnings FAQ
How does RNXT stock usually react to earnings?
Across the last 2 reports the average next-day move was ±3.2%, up 2 times and down 0 times.